Bunsua, Merly L.

HRN: 29-05-76  Sex: Female

Patient Encounter


Audit Details

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
06/19/2026
METRONIDAZOLE 5MG/ML, 100ML (VIAL)
06/19/2026
06/25/2026
IV
500mg
Q8
Infected Breast Mass, Left
Checking Initial Appropriateness 

 Indication:  Empiric    Type of Infection:  Skin & Soft Tissue    Compliance to guidelines: Compliant To Guidelines